These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19119321)

  • 1. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
    Moorthy A; Gupta A; Bhosale R; Tripathy S; Sastry J; Kulkarni S; Thakar M; Bharadwaj R; Kagal A; Bhore AV; Patil S; Kulkarni V; Venkataramani V; Balasubramaniam U; Suryavanshi N; Ziemniak C; Gupte N; Bollinger R; Persaud D
    PLoS One; 2009; 4(1):e4096. PubMed ID: 19119321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
    Persaud D; Bedri A; Ziemniak C; Moorthy A; Gudetta B; Abashawl A; Mengistu Y; Omer SB; Isehak A; Kumbi S; Adamu R; Lulseged S; Ashworth R; Hassen E; Ruff A;
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):823-9. PubMed ID: 21241214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral interventions for preventing breast milk transmission of HIV.
    White AB; Mirjahangir JF; Horvath H; Anglemyer A; Read JS
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD011323. PubMed ID: 25280769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
    Church JD; Omer SB; Guay LA; Huang W; Lidstrom J; Musoke P; Mmiro F; Jackson JB; Eshleman SH
    J Infect Dis; 2008 Oct; 198(7):1075-82. PubMed ID: 18684096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
    Hudelson SE; McConnell MS; Bagenda D; Piwowar-Manning E; Parsons TL; Nolan ML; Bakaki PM; Thigpen MC; Mubiru M; Fowler MG; Eshleman SH
    AIDS; 2010 Feb; 24(4):557-61. PubMed ID: 20057308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
    Permar SR; Salazar MG; Gao F; Cai F; Learn GH; Kalilani L; Hahn BH; Shaw GM; Salazar-Gonzalez JF
    Retrovirology; 2013 Aug; 10():88. PubMed ID: 23941304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
    Fogel J; Hoover DR; Sun J; Mofenson LM; Fowler MG; Taylor AW; Kumwenda N; Taha TE; Eshleman SH
    AIDS; 2011 Apr; 25(7):911-7. PubMed ID: 21487249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.
    Lidström J; Li Q; Hoover DR; Kafulafula G; Mofenson LM; Fowler MG; Thigpen MC; Kumwenda N; Taha TE; Eshleman SH
    AIDS; 2010 Jan; 24(3):381-6. PubMed ID: 19996936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique.
    Micek MA; Dross S; Blanco AJ; Beck IA; Matunha L; Seidel K; Montoya P; Matediana E; Gantt S; Gloyd S; Frenkel L
    J Infect Dis; 2014 Aug; 210(4):641-5. PubMed ID: 24596282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
    Frank M; von Kleist M; Kunz A; Harms G; Schütte C; Kloft C
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5529-40. PubMed ID: 21947390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for preventing late postnatal mother-to-child transmission of HIV.
    Horvath T; Madi BC; Iuppa IM; Kennedy GE; Rutherford G; Read JS
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD006734. PubMed ID: 19160297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
    AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
    Church JD; Mwatha A; Bagenda D; Omer SB; Donnell D; Musoke P; Nakabiito C; Eure C; Bakaki P; Matovu F; Thigpen MC; Guay LA; McConnell M; Fowler MG; Jackson JB; Eshleman SH
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):673-7. PubMed ID: 19552593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
    Martinson NA; Morris L; Gray G; Moodley D; Pillay V; Cohen S; Dhlamini P; Puren A; Bhayroo S; Steyn J; McIntyre JA
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):148-53. PubMed ID: 17117145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
    Flys TS; McConnell MS; Matovu F; Church JD; Bagenda D; Khaki L; Bakaki P; Thigpen MC; Eure C; Fowler MG; Eshleman SH
    J Infect Dis; 2008 Aug; 198(4):465-9. PubMed ID: 18582198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
    Taha TE; Kumwenda NI; Hoover DR; Fiscus SA; Kafulafula G; Nkhoma C; Nour S; Chen S; Liomba G; Miotti PG; Broadhead RL
    JAMA; 2004 Jul; 292(2):202-9. PubMed ID: 15249569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    Kumwenda NI; Hoover DR; Mofenson LM; Thigpen MC; Kafulafula G; Li Q; Mipando L; Nkanaunena K; Mebrahtu T; Bulterys M; Fowler MG; Taha TE
    N Engl J Med; 2008 Jul; 359(2):119-29. PubMed ID: 18525035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
    Larsen A; Magasana V; Dinh TH; Ngandu N; Lombard C; Cheyip M; Ayalew K; Chirinda W; Kindra G; Jackson D; Goga A
    BMC Infect Dis; 2019 Sep; 19(Suppl 1):789. PubMed ID: 31526366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.